Population pharmacokinetics of NNZ‐2566 in healthy subjects

[1]  C. V. van Karnebeek,et al.  Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future. , 2016, Pediatric neurology.

[2]  D. Tropea,et al.  Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders , 2016, Front. Neurosci..

[3]  M. Danhof,et al.  Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β‐Thalassemia , 2016, Journal of clinical pharmacology.

[4]  A. Percy.  Progress in Rett Syndrome: from discovery to clinical trials , 2016, Wiener Medizinische Wochenschrift.

[5]  S. Moshé,et al.  Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. , 2016, Pediatric neurology.

[6]  M. Sur,et al.  Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome , 2014, Proceedings of the National Academy of Sciences.

[7]  M. Gill,et al.  Repeated Insulin-Like Growth Factor 1 Treatment in a Patient with Rett Syndrome: A Single Case Study , 2014, Front. Pediatr..

[8]  M. Danhof,et al.  Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. , 2014, British journal of clinical pharmacology.

[9]  Heather M. O'Leary,et al.  Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome , 2014, Proceedings of the National Academy of Sciences.

[10]  G. Hempel,et al.  Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children , 2012, Cancer Chemotherapy and Pharmacology.

[11]  P. Gluckman,et al.  NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke , 2009, Journal of the Neurological Sciences.

[12]  Nathan R. Wilson,et al.  Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice , 2009, Proceedings of the National Academy of Sciences.

[13]  S. Tett,et al.  A Bayesian approach for population pharmacokinetic modelling of sirolimus. , 2006, British journal of clinical pharmacology.

[14]  M. Preece,et al.  Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[15]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[16]  J. Gécz,et al.  Rett syndrome: clinical review and genetic update , 2005, Journal of Medical Genetics.

[17]  P. Gluckman,et al.  Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. , 2003, Analytical biochemistry.

[18]  M. Msall,et al.  Describing the phenotype in Rett syndrome using a population database , 2003, Archives of disease in childhood.

[19]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[20]  A. Forrest,et al.  Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime , 1996, Antimicrobial agents and chemotherapy.

[21]  F. Hanefeld,et al.  Rett syndrome: Criteria for inclusion and exclusion , 1985, Brain and Development.

[22]  W. Jusko,et al.  Distribution volume related to body weight and protein binding. , 1982, Journal of pharmaceutical sciences.

[23]  Malcolm Rowland,et al.  Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  A Rett,et al.  [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. , 1966, Wiener medizinische Wochenschrift.

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[27]  R. Prescott,et al.  Rett syndrome: analysis of deaths in the British survey. , 1997, European child & adolescent psychiatry.